Intervention Review
Puerarin for acute ischaemic stroke
Editorial Group: Cochrane Stroke Group
Published Online: 21 JAN 2009
Assessed as up-to-date: 2 OCT 2006
DOI: 10.1002/14651858.CD004955.pub2
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Database Title
Additional Information
How to Cite
Tan Y, Liu M, Wu B. Puerarin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD004955. DOI: 10.1002/14651858.CD004955.pub2.
Publication History
- Publication Status: Edited (no change to conclusions)
- Published Online: 21 JAN 2009
Abstract
Background
Puerarin, a form of herbal medicine, is widely used in the treatment of acute ischaemic stroke in China.
Objectives
To assess the efficacy and safety of puerarin in patients with acute ischaemic stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (last searched August 2006), the Trials Register of the Cochrane Complementary Medicine Field (last searched June 2006) and the Chinese Stroke Trials Register (last searched June 2006). In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (1966 to August 2006), EMBASE (1980 to June 2006), AMED (1985 to June 2006) and the China Biological Medicine Database (CBM-disc, 1979 to June 2006). We searched reference lists, relevant clinical trials and research registers and contacted pharmaceutical companies and researchers in an effort to identify further published and unpublished studies.
Selection criteria
Randomised controlled trials or quasi-randomised controlled clinical trials comparing puerarin with placebo or open control (no placebo) in patients with acute ischaemic stroke.
Data collection and analysis
Two review authors independently applied the inclusion criteria, assessed trial quality and extracted the data.
Main results
One trial, involving 98 participants, was included. No significant difference in death or dependency was shown between the treatment and control groups (odds ratio (OR) 0.81; 95% confidence interval (CI) 0.35 to 1.87). No serious adverse effects were reported.
Authors' conclusions
There is not enough evidence to evaluate the effect of puerarin on survival or dependency of patients with acute ischaemic stroke. High-quality and large-scale randomised controlled trials are needed to assess its efficacy.
Plain language summary
Puerarin for acute ischaemic stroke
Puerarin, a form of herbal medicine, is widely used in China. We reviewed evidence from randomised or quasi-randomised controlled trials investigating puerarin in patients with acute ischaemic stroke. This review of one trial, involving 98 participants, showed no clear effect of puerarin for ischaemic stroke. No serious adverse effects were reported. There is insufficient evidence that puerarin may be helpful with the management of acute ischaemic stroke. Results from much larger randomised trials are needed to assess accurately the benefits and harms of puerarin in acute ischaemic stroke.
摘要
背景
Puerarin治療急性缺血性中風
Puerarin，一種草藥，在中國被廣泛用於治療急性缺血性中風
目標
評估使用Puerarin用在急性缺血性中風病人的效果與安全性
搜尋策略
我們檢索了Cochrane腦中風組試驗註冊資料庫(最後搜查至2006年8月)，Cochrane非傳統醫療領域試驗註冊資料庫(最後搜查至2006年6月)和中國腦中風試驗註冊(最後搜查至2006年6月)。此外，我們檢索了Cochrane中心對照試驗註冊(CENTRAL)(Cochrane圖書館第1期，2006)，MEDLINE(1966年至2006年8月)，EMBASE(1980年至2006年6月)，AMED(1985年至2006年6月)和中國生物醫學文獻資料庫(CBMdisc，1979年至2006年6月)。我們檢索了參考文獻，相關臨床試驗和研究登錄,也接觸製藥公司和研究人員，以便確定進一步會發表和未發表的研究。
選擇標準
比較puerarin與安慰劑或開放控制(無安慰劑)治療急性缺血性中風的隨機對照試驗或半隨機對照臨床試驗。
資料收集與分析
2位回顧者獨立地使用試驗收錄標準來選取試驗並評估試驗品質及摘錄數據
主要結論
一個試驗，涉及98名參與者，被收錄在內。結果為死亡或失能在治療組和對照組之間並無顯著差異，(危險比(OR)0.81; 95％信賴區間(CI)0.35至1.87)。無嚴重不良反應被報告。
作者結論
沒有足夠的證據來評論puerarin 對急性缺血性中風患者是否會生存或失能。需要高品質，大規模的隨機對照試驗來評估其療效。
翻譯人
本摘要由奇美醫院何乘彰翻譯。
此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。
總結
Puerarin治療急性缺血性中風: Puerarin，一種草藥，在中國被廣泛使用. 我們回顧了使用Puerarin治療急性缺血性中風的隨機或半隨機對照試驗證據。本回顧的一個試驗，涉及98名參與者，顯示Puerarin對缺血性中風沒有明顯的影響。無嚴重不良反應報告。沒有足夠的證據表明Puerarin能有助於處理急性缺血性中風。需要從更大的隨機試驗，以準確評估Puerarin用於急性缺血性中風的好處和危害。